Tumor Biology

, Volume 35, Issue 7, pp 6695–6700 | Cite as

Correlation between overexpression of EpCAM in prostate tissues and genesis of androgen-dependent prostate cancer

Research Article

Abstract

The objective of this study was to investigate the role of epithelial cell adhesion molecule (EpCAM) in the genesis and the progress of prostate cancer, especially of castration-resistant prostate cancer. Protein expression of EpCAM in ten pairs of prostate cancer tissues and normal adjacent tissues, plus three cell lines, was examined. Short hairpin RNA (shRNA) interference technique was employed to silence the expression of EpCAM in prostate cancer cell LNCaP and construct a stable transfected cell line. In vitro assay was conducted to analyze the effect of EpCAM expression on the expressions of Androgen receptor (AR), Prostate specific antigen (PSA), and cellular proliferation and invasion. EpCAM was found significantly expressed higher in prostate cancer tissues than in normal adjacent tissues. In three cell lines (DU-145, PC-3, and LNCaP), the expression of EpCAM in LNCaP, androgen-dependent prostate cancer cells, was significantly higher than that in the other two. As EpCAM was silenced in LNCaP, the expression levels of AR and PSA obviously descended, and cellular abilities of proliferation and invasion were obviously inhibited.The overexpression of EpCAM has correlation with the genesis of prostate cancer, especially androgen-dependent prostate cancer. As the expression of AR is facilitated, prostate cancer cells’ abilities to proliferate and invade are consequently enhanced.

Keywords

EpCAM Prostate cancer Androgen receptor PSA 

Notes

Conflicts of interest

None.

References

  1. 1.
    Calabrò F, Sternberg CN. Current indications for chemotherapy in prostate cancer patients. Eur Urol. 2007;51(1):17–26.CrossRefPubMedGoogle Scholar
  2. 2.
    Higano CS, Crawford ED. New and emerging agents for the treatment of castration-resistant prostate cancer. Urol Oncol. 2011;29(6 Suppl):S1–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Petrylak DP. Future directions in the treatment of androgen-independent prostate cancer. Urology. 2005;65(6 Suppl):8–12.CrossRefPubMedGoogle Scholar
  4. 4.
    Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer. 2007;96(3):417–23.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Patriarca C, Macchi RM, Marschner AK, Mellstedt H. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev. 2012;38(1):68–75.CrossRefPubMedGoogle Scholar
  6. 6.
    Kimura H, Kato H, Faried A, Sohda M, Nakajima M, Fukai Y, et al. Prognostic significance of EpCAM expression in human esophageal cancer. Int J Oncol. 2007;30(1):171–9.PubMedGoogle Scholar
  7. 7.
    Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol. 2007;171(2):386–95.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, Rots MG. EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis. 2010;31(11):1913–21.CrossRefPubMedGoogle Scholar
  9. 9.
    Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, et al. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat. 2004;86(3):207–13.CrossRefPubMedGoogle Scholar
  10. 10.
    Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer. 2006;94(1):128–35.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Poczatek RB, Myers RB, Manne U, Oelschlager DK, Weiss HL, Bostwick DG, et al. Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J Urol. 1999;162(4):1462–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin HJ, et al. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer. 2005;113(4):619–28.CrossRefPubMedGoogle Scholar
  13. 13.
    Benko G, Spajić B, Krušlin B, Tomas D. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer. Urol Oncol. 2013;31(4):468–74.CrossRefPubMedGoogle Scholar
  14. 14.
    Dehm SM, Tindall DJ. Regulation of androgen receptor signaling in prostate cancer. Expert Rev Anticancer Ther. 2005;5(1):63–74.CrossRefPubMedGoogle Scholar
  15. 15.
    Li Y, Hwang TH, Oseth LA, Hauge A, Vessella RL, Schmechel SC, et al. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene. 2012;31(45):4759–67.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst. 2001;93(22):1687–97.CrossRefPubMedGoogle Scholar
  17. 17.
    Eskander RN, Tewari KS. Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer. Clin Pharmacol. 2013;5 Suppl 1:55–61.PubMedCentralPubMedGoogle Scholar
  18. 18.
    Hao H, Zhen Y, Wang Z, Chen F, Xie X. A novel therapeutic drug for colon cancer: EpCAM scFv-truncated protamine (tp)-siRNA. Cell Biol Int. 2013;37(8):860–4.CrossRefPubMedGoogle Scholar
  19. 19.
    Gires O, Bauerle PA. EpCAM as a target in cancer therapy. J Clin Oncol. 2010;28(15):e239–40.CrossRefPubMedGoogle Scholar
  20. 20.
    Gutheil JC. Novel immunologic and biologic therapies for breast cancer. Curr Oncol Rep. 2000;2(6):582–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Sun W, Haller DG. Adjuvant therapy of colon cancer. Semin Oncol. 2005;32(1):95–102.CrossRefPubMedGoogle Scholar
  22. 22.
    Frampton JE. Catumaxomab: in malignant ascites. Drugs. 2012;72(10):1399–410.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of UrologyThe First Affiliated Hospital of Soochow UniversitySuzhouChina
  2. 2.Department of UrologyJiangsu Jiangyin People’s HospitalJiangyinChina

Personalised recommendations